Reshema Kemps-Polanco is Executive Vice President and US Head, Novartis Oncology, responsible for the commercialization of innovative cancer medicines, including complex platforms such as cell and gene therapy, and radiopharmaceuticals. With over 20 years of U.S. and global healthcare experience, she is pursuing a transformational growth strategy to sustain a leading position in the world’s largest healthcare market across oncology and hematologic diseases.

Reshema returned to Novartis in 2021 after spending seven years at Johnson and Johnson, where she served as President of Janssen’s Cardiovascular and Metabolism Unit in the U.S. and concurrently as President, Janssen Pharmaceuticals, Puerto Rico. Prior positions at Janssen include serving as Vice President across multiple roles in the U.S., as well as the Global Oncology organization. Before joining Johnson and Johnson, Reshema spent 15 years at Novartis where she led multiple commercial teams across oncology and specialty business units.

Reshema is a board member of the Healthcare Leadership Council, a coalition of chief executives focused on policies that make quality healthcare accessible to all Americans.

Reshema earned an M.B.A from Rutgers University, and M.A. in Industrial/Organizational Development from Louisiana Tech University and a B.A. from the University of Louisiana at Monroe.